Drug intelligence / Profile preview

Bionetide

Development stage: Phase 3
Lead developer: Biomed
Modality: Small Molecules
Administration: Oral

Overview

Bionetide (NA-921) is a small molecule drug developed by Biomed Industries, Inc. It is currently in Phase 3 clinical trials for the treatment of Rett Syndrome and Fragile X Syndrome. Administered orally, Bionetide is designed to readily cross the blood-brain barrier. Its mechanism of action involves modulating MECP2 expression, thereby addressing the core epigenetic dysfunction associated with Rett Syndrome. The drug also promotes neuroprotection and neurogenesis. Clinical trial results suggest a favorable safety profile compared to existing treatments for Rett Syndrome.

Targets

MECP2 (Methyl-CpG-binding protein 2)GLP1R (GLP-1R)IGF-1 (Insulin-like growth factor 1)

Beyond the preview

Go deeper on Bionetide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionetide.

Explore the full profile